The influence of SARS-CoV-2 vaccination on 28-day mortality and hospitalization rate of COVID-19 patients under 40 years

Öz

Purpose: The purpose of our research is to determine the protective impact of CoronaVac vaccine in individuals under the age of 40 and over the age of 18 who have had COVID-19 infection. Material and Methods: Patients aged 18-40 years who applied to our hospital with COVID-19 + as a test were divided into two groups according to their coronaVac vaccine status, and the morbidity and mortality of the patients were investigated. Results: In the present research, the total mortality ratio in the unvaccinated patient group was 8.2%, while the overall mortality rate in the patient group vaccinated was 0% (p = .043). Conclusion: The 0% mortality rate in persons who received two doses of CoronaVac vaccine clearly shows the effect of the vaccine on mortality.

Anahtar Kelimeler

• CoronaVac
• age
• vaccine.

Kaynakça

1. Amato, M. K., Hennessy, C., Shah, K., Mayer, J. (2021).Multisystem Inflammatory Syndrome in an Adult. The Journal of emergency medicine, 61(1), 1–3. https://doi.org/10.1016/j.jemermed.2021.02.007
2. Chaimayo, C., Kaewnaphan, B., Tanlieng, N., Athipanyasilp, N., Sirijatuphat, R., Chayakulkeeree, M., Angkasekwinai, N., Sutthent, R., Puangpunngam, N.,Tharmviboonsri, T., Pongraweewan, O., Chuthapisith, S., Sirivatanauksorn, Y., Kantakamalakul, W.,Horthongkham, N. (2020). Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCRassay for laboratory diagnosis of COVID-19 in Thailand. Virology journal, 17(1), 177. https://doi.org/10.1186/s12985-020-01452-5
3. Chen LK. (2021). COVID‐19 vaccination and frailty in older adults. Arch Gerontol Geriatr, 96:104487. https://doi: 10.1016/j.archger.2021.104487
4. Cömert, SŞ., Kıral, N. (2020). Radiological Findings ofCOVID-19 Pneumonia. Southern Clinics of Istanbul Eurasia, 31: 16-22.https://doi.org/10.14744/scie.2020.96158
5. Diken ÖE. (2021). SARS-CoV, MERS-CoV Neler Öğrendik? SARS-CoV2 ile Farklılıkları. ASYOD Güncel Göğüs Hastalıkları Serisi Kitapları. In: Karadağ M. Ankara: Dünya Tıp Kitapevi. 35-43.
6. Eastin, C., Eastin, T. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China: Guan W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI: 10.1056/NEJMoa2002032. The Journal of Emergency Medicine, 58(4), 711–712. https://doi.org/10.1016/j.jemermed.2020.04.004
7. Fang, X., Li, S., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H., Ma, X. (2020). Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and metaanalysis. Aging, 12(13), 12493–12503.
8. https://doi.org/10.18632/aging.103579 Ganesan, R., Mahajan, V., Singla, K., Konar, S., Samra, T., Sundaram, S. K., Suri, V., Garg, M., Kalra, N., Puri, G. D.(2021). Mortality Prediction of COVID-19 Patients at Intensive Care Unit Admission. Cureus, 13(11), 19690. https://doi.org/10.7759/cureus.19690

9. Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y.,Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., Li, J., … Qin, C.(2020). Development of an inactivated vaccinecandidate for SARS-CoV-2. Science (New York,N.Y.), 369(6499), 77–81. https://doi.org/10.1126/science.abc1932
10. Hani, C., Trieu, N. H., Saab, I., Dangeard, S., Bennani, S.,Chassagnon, G., Revel, M. P. (2020). COVID-19 pneumonia: A review of typical CT findings and differential diagnosis. Diagnostic and interventional imaging, 101(5), 263–268. https://doi.org/10.1016/j.diii.2020.03.014
11. Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., Pollard, A. J. (2021). What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet. Infectious diseases, 21(2), 26–35. https://doi.org/10.1016/S1473-3099(20)30773-8
12. Hussin, A., Rothan and Siddappa, N. Byrareddy. (2020).The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun, 09: 102433. https://doi.org/10.1016/j.jaut.2020.102433
13. Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., Sans, C., Leighton, P., Suárez, P., GarcíaEscorza, H., Araos, R. (2021). Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. The New England journal of medicine, 385(10), 875–884. https://doi.org/10.1056/NEJMoa2107715
14. Liu, W., Tao, Z. W., Wang, L., Yuan, M. L., Liu, K., Zhou, L., Wei, S., Deng, Y., Liu, J., Liu, H. G., Yang, M., Hu, Y. (2020). Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal, 133(9),1032–1038. https://doi.org/10.1097/CM9.0000000000000775
15. McGill COVID19 Vaccine Tracker Team. Sinovac: CoronaVac. https://covid19.trackvaccines.org/vaccines/7/ (accessed April 28, 2021).
16. Inactivated SARS-CoV-2 vaccine candidates have shown promising results in preclinical trials 13. Palacios, R., Batista. AP., Albuquerque. CSN., Patiño. EG.,
17. Santos. JdP., Conde. MTRP., Piorelli. RdO., Júnior. LCP., Raboni. SM., Ramos. F., Romero. GAS., Leal. FE., Camargo. LFA., Aoki. FH., Coelho. EB., Oliveira. DS., Fontes. CJF., Pileggi. GCS., Oliveira. ALLd., Siqueira. AMd., Oliveira. DBLd., Botosso. VF., Zeng. G., Xin. Q., Teixeira. MM., Nogueira. ML., Kallas. EG. (2021). Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN.
18. Pan, F., Ye, T., Sun, P., Gui, S., Liang, B., Li, L., Zheng, D.,Wang, J., Hesketh, R. L., Yang, L., Zheng, C. (2020). Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID19). Radiology, 295(3), 715–721. https://doi.org/10.1148/radiol.2020200370
19. Roghani, A. (2021). The Influence of Covid-19 Vaccine on Daily Cases, Hospitalization, and Death Rate in Tennessee: A Case Study inthe United States. MedRxiv. https://doi.org/10.2196/29324
20. Song, J. Y., Yun, J. G., Noh, J. Y., Cheong, H. J., Kim, W. J. (2020). Covid-19 in South Korea - Challenges of Subclinical Manifestations. The New England journal of medicine, 382(19), 1858–1859. https://doi.org/10.1056/NEJMc2001801
21. Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdinç, F. Ş., Akalın, E. H., Tabak, Ö. F., Pullukçu, H., Batum, Ö., Şimşek Yavuz, S., Turhan, Ö., Yıldırmak, M. T., Köksal, İ., Taşova, Y., Korten, V., Yılmaz, G., Çelen, M. K., CoronaVac Study Group (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey. Lancet (London, England), 398(10296), 213–222. https://doi.org/10.1016/S0140-6736(21)01429-X
22. Vasileiou, E., Simpson, C. R., Shi, T., Kerr, S., Agrawal, U., Akbari, A., Bedston, S., Beggs, J., Bradley, D., Chuter, A., de Lusignan, S., Docherty, A. B., Ford, D., Hobbs, F. R., Joy, M., Katikireddi, S. V., Marple, J., McCowan, C., McGagh, D., McMenamin, J., … Sheikh, A. (2021). Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet (London, England), 397(10285), 1646– 1657. https://doi.org/10.1016/S0140-6736(21)00677- 2
23. Wilder-Smith, A., Mulholland, K. (2021). Effectiveness of an Inactivated SARS-CoV-2 Vaccine. N Engl J Med, 385(10): 946–948. https://doi.org/10.1056/NEJMe2111165.
24. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. (2022a). Available from https://covid19.who.int/
25. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. TÜRKİYE; (2022b). Available from https://covid19.who.int/region/euro/country/tr.
26. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. (2022c). Available from https://www.who.int/news-room/featurestories/detail/the-sinovac-covid-19-vaccine-whatyou-need-to-know.
27. Yang, L., Liu, J., Zhang, R., Li, M., Li, Z., Zhou, X., Hu, C., Tian,F., Zhou, F., Lei, Y. (2020). Epidemiological and clinical features of 200 hospitalized patients with corona virusdisease 2019 outside Wuhan, China: A descriptive study. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology, 129, 104475. https://doi.org/10.1016/j.jcv.2020.104475
28. Ye, Z., Zhang, Y., Wang, Y., Huang, Z., Song, B. (2020). Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. European radiology, 30(8), 4381–4389. https://doi.org/10.1007/s00330-020-06801-0
29. Yorsaeng, R., Suntronwong, N., Phowatthanasathian, H., Assawakosri, S., Kanokudom, S., Thongmee, T., Vichaiwattana, P., Auphimai, C., Wongsrisang, L., Srimuan, D., Thatsanatorn, T., Klinfueng, S., Sudhinaraset, N., Wanlapakorn, N., Poovorawan, Y. (2022). Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine, 40(3), 524–530. https://doi.org/10.1016/j.vaccine.2021.11.083
30. Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4
31. Zhang, Z. L., Hou, Y. L., Li, D. T., Li, F. Z. (2020). Laboratory findings of COVID-19: a systematic review and metaanalysis. Scandinavian journal of clinical and laboratory investigation, 80(6), 441–447. https://doi.org/10.1080/00365513.2020.1768587